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Aim To analyze the sex-specific incidence and mortality 
trends of brain malignancies in Croatia from 2001 to 2014.
Methods Incidence and mortality rates per 100 000 popu-
lation were calculated using data obtained from the Croa-
tian National Cancer Registry and the Croatian Bureau of 
Statistics. Rates were age-standardized to the European 
Standard Population, and trends were assessed using join-
point regression.
Results In the observed period there were 6634 new 
brain malignancy cases (52% men) and 5379 deaths due 
to this diagnosis (52% men). Age-standardized incidence 
rates ranged from 9.2-11.5 per 100 000 in men and from 
7-8.8 per 100 000 in women. Mortality rates ranged from 
7.5-8.7 per 100 000 in men and from 5-6.5 in women. In-
cidence trends in men, mortality in men, and mortality in 
women were not statistically significant, while a significant 
trend was observed in incidence in women (annual per-
cent change -1.5; 95% confidence interval -2.3 to -0.6). No 
joinpoints were observed in any of the joinpoint analyses 
by sex for incidence and mortality. Age-specific incidence 
and mortality rates in both sexes indicate a trend shift to-
ward older age. The proportion of morphologically verified 
cases ranged from 40.2%-62.4% in men and from 38.6%-
56.3% in women; the proportion of death-certificate-only 
cases ranged from 3.3%-9.4% in men and from 3.3%-17.5% 
in women.
Conclusion Incidence and mortality of brain malignancies 
in Croatia are among the highest in Europe, while report-
ing on brain malignancies is still poor. There is a need for 
improved care of patients with brain malignancies and de-
tailed and accurate data reporting.
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Although brain malignancies account for approximately 
1.8% of all malignancies worldwide (five-year prevalence), 
some of the histological types are among the most aggres-
sive malignancies (1). Overall, 20% of adults diagnosed with 
a primary brain malignancy between 2000 and 2007 in Eu-
rope survived 5 years after diagnosis (2). Despite increase 
in one-year relative survival rates in the same period and 
population, survival remains poor (2). Between 1993 and 
2007, the incidence of brain malignancies in most coun-
tries worldwide was stable (3).
Brain malignancies are classified according to the WHO 
Classification of the Tumors of the Central Nervous System 
(CNS), which was updated in 2016 and includes over 120 
entities (4). The incidence and survival for brain malignan-
cies vary significantly by age and histological type (2). Epi-
demiologic data on brain malignancies are mostly collect-
ed from population-based cancer registries, as is the case 
with Croatia, where brain malignancies in 2014 accounted 
for 2.2% of all new cancer cases (5). However, imperfec-
tions in data collection and inconsistent usage of diagnos-
tic criteria hamper the comparison of epidemiological data 
across different countries or regions (6).
According to the recent estimates (data for both sexes 
combined) of the European Cancer Information System 
for 2018, Croatia ranks fourth in incidence and second 
in mortality of malignant brain and CNS tumors (7). Thus 
far, Croatian epidemiologic data trends on brain malig-
nancies have been reported in a publication from 2017, 
which reported incidence data from 1993-2007 as a part 
of an analysis of global patterns and incidence (3) and in 
a series of articles on childhood, adolescents, and young 
adults’ brain and CNS malignancies as a part of the co-
operation of the South-Eastern Europe cancer registries 
(8-12). Croatian data on brain malignancy incidence have 
also been included in Volumes IX, X, and XI of the Cancer 
Incidence in Five Continents publications (13-15). Oth-
er epidemiologic data on brain malignancies in Croatia 
are published in the yearly bulletins of the Croatian Na-
tional Cancer Registry (5). However, long-term trends in 
incidence and mortality of brain malignancies in Croatia 
have not been reported. Therefore, the aim of this study 
was to provide an overview of these indices from 2001 
to 2014.
METHODS
The incidence and mortality data were obtained from 
the Croatian National Cancer Registry (CNCR). The CNCR 
is a population-based cancer registry that collects data 
on new cases of cancer in the Croatian population. Its 
data sources include mandatory reports by the primary 
and secondary health care providers, pathology reports, 
and death certificates from the Croatian Bureau of Sta-
tistics. Brain malignancies were defined according to the 
ICD, 10th revision, code C71. To calculate incidence and 
mortality rates per 100 000 population, we used popula-
TABlE 1. Incidence and mortality from brain malignancies in Croatia, 2001-2014
Men Women
incidence mortality incidence mortality
Year number ASR* (E) number ASR (E) number ASR (E) number ASR (E)
2001 249 11.29 179 7.87 223 8.44 147 5.01
2002 240 10.77 176 7.57 233 8.51 162 5.25
2003 268 11.52 198 8.28 237 8.75 176 5.83
2004 262 11.29 206 8.51 224 7.95 172 5.46
2005 237 10.20 182 7.61 251 8.70 181 5.73
2006 230  9.57 189 7.55 230 8.19 179 5.70
2007 259 11.06 195 7.93 196 6.97 181 5.97
2008 243 10.03 212 8.62 207 7.09 165 4.97
2009 267 11.08 210 8.50 228 7.22 188 5.63
2010 219  9.22 222 8.72 246 7.79 209 6.19
2011 262 10.85 192 7.51 244 7.72 225 6.52
2012 234  9.65 216 8.32 214 7.04 196 5.54
2013 226  9.40 203 8.12 213 7.11 194 6.01
2014 267 10.84 222 8.61 225 7.46 202 5.56
2001-2014 3463 10.53 2802 8.16 3171 7.82 2577 5.70
*ASR – age-standardized rate; E – the European Standard Population.
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tion estimates for years 2001-2014 from the Croatian Bu-
reau of Statistics. The European Standard Population from 
1976 was used as a reference when calculating age-stan-
dardized rates (ASR) (16).
To describe incidence and mortality time trends of brain 
malignancies in Croatia, we carried out a joinpoint regres-
sion analysis of age-standardized rates using Joinpoint 
Regression Program, Version 4.6.0.0, from April 2018; Sta-
tistical Methodology and Applications Branch, Surveil-
lance Research Program, National Cancer Institute. This 
approach determines age-standardized cancer incidence 
and mortality rates along with respective standard errors 
and fits the simplest model possible, starting with the 
model with zero joinpoints (17). Using Monte Carlo Permu-
tation method, this approach tests whether adding addi-
tional joinpoints (up to a previously defined maximum) is 
significant. For the period between two joinpoints (or the 
beginning and the end of series), a log-linear model with 
annual percent change (APC) is calculated as a trend mea-
sure, with its corresponding confidence intervals (CI). The 
analysis included logarithmic transformation of the rates, 
standard error for heteroscedasticity, maximum number of 
two joinpoints, a minimum of two years between two join-
points, and a minimum of two years between a joinpoint 
and the beginning or end of the series. A permutation test 
was used with a significance level set at P < 0.05. All tests 
were two-sided.
RESUlTS
From 2001 to 2014 there were 6634 reported cases of brain 
malignancies in Croatia, 52% of which were in men. There 
were 5379 deaths due to brain malignancies, 52% of which 
were in men. The number of annually newly diagnosed cas-
es ranged from 439 in 2013 to 506 in 2011. Age-standard-
ized incidence rates ranged from 9.2 to 11.5 per 100 000 in 
men and from 7 to 8.8 per 100 000 in women; the mortality 
rates ranged from 7.5 to 8.7 per 100 000 in men and from 
5 to 6.5 in women (Table 1). Incidence trends in men (APC 
-0.9; 95% CI -1.8 to 0.1), mortality in men (APC 0.5; 95% CI 
-0.3 to 1.3), and mortality in women (APC 0.8; 95% CI -0.2 
to 1.9) were not significant, while a significant trend was 
observed in incidence in women (APC -1.5; 95% CI -2.3 to 
-0.6) (Figures 1 and 2). No joinpoints were observed in any 
of the sex-specific regression analyses for incidence and 
mortality.
Regarding specific entities within this group of diseases, 
the rates of cases with unknown histologic tumor type 
ranged from 41% in 2010 to 59% in 2001. Given the impre-
cise and informative nature of these data, incidence and 
mortality rates were not calculated by individual patho-
logic entities.
Age-specific incidence rates of brain malignancies in men, 
calculated for three separate periods (2001-2005; 2006-
2010; 2011-2014), showed a shift in distribution toward old 
FIGURE 1. Age-standardized (E) incidence rates of brain malignancies for 2001-2014 period, Croatia, by sex. Triangle – men; circle – 
women; blue line – men modeled; green line – women modeled. E – the European Standard Population.
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age in the period between 2001 and 2014 (Figure 3). Age-
specific mortality rates for men in the same period showed 
a shift toward younger age, with peak rates in the age 
group 75-79 (Figure 4). Age-specific incidence and mortal-
ity rates in women also showed a shift toward older age, 
which is particularly evident in mortality rate increase in 
the age group 85 and older (Figures 5 and 6).
The proportion of morphologically verified cases ranged 
from 40.2 to 62.4% in men and from 38.6 to 56.3% in wom-
en; the proportion of death-certificate-only cases ranged 
from 3.3 to 9.4% in men and from 3.3 to 17.5% in women 
(Table 2).
DISCUSSION
Incidence data obtained in our study ranged from 9.2 to 
11.5 per 100 000 in men and from 7 to 8.8 per 100 000 
in women, which is in line with the estimates of the in-
cidence of brain and nervous system malignancies from 
FIGURE 2. Age-standardized (E) mortality rates of brain malignancies for 2001-2014 period, Croatia, by sex. Triangle – men; circle – 
women; blue line – men modeled; green line – women modeled. E – the European Standard Population.















2001 40.2 3.3 0.72 42.6 6.7 0.66
2002 46.6 3.0 0.73 47.0 6.4 0.70
2003 43.8 6.6 0.74 42.7 3.3 0.74
2004 53.1 7.3 0.79 46.0 9.4 0.77
2005 46.3 3.7 0.77 38.6 4.3 0.72
2006 51.3 5.2 0.82 50.6 6.8 0.78
2007 62.4 4.3 0.75 55.7 6.7 0.92
2008 48.8 8.6 0.87 44.5 10.4 0.80
2009 61.0 7.9 0.79 56.3 11.6 0.82
2010 58.5 9.4 1.01 50.6 11.0 0.85
2011 51.5 6.3 0.73 39.4 12.0 0.92
2012 44.9 7.3 0.92 45.1 13.6 0.92
2013 47.5 7.2 0.90 40.6 12.8 0.91
2014 55.1 6.7 0.83 52.8 17.5 0.90
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FIGURE 3. Age-specific incidence rate of brain malignancies in men for different time periods. Dotted line – 2001-2005; dashed line – 
2006-2010; full line – 2011-2014.
FIGURE 4. Age-specific mortality rate of brain malignancies in men for different time periods. Dotted line – 2001-2005; dashed line – 
2006-2010; full line – 2011-2014.
PUBLIC HEALTH38 Croat Med J. 2019;60:33-41
www.cmj.hr
FIGURE 5. Age-specific incidence rate of brain malignancies in women for different time periods. Dotted line – 2001-2005; dashed 
line – 2006-2010; full line – 2011-2014.
FIGURE 6. Age-specific mortality rate of brain malignancies in women for different time periods. Dotted line – 2001-2005; dashed 
line – 2006-2010; full line – 2011-2014.
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2018 (1,7) and 2017 (3). In the latter report, age-standard-
ized incidence rate in Croatian men was 12.0 per 100 000, 
second only to Brazil (13.3), and the incidence in women 
(9.4) was highest among the included countries (3). This 
report obtained the incidence data from the national reg-
istry, the same source used in this study; however, they in-
cluded ICD-10 diagnoses C70-C72, while we included only 
C71 diagnoses. Also, they analyzed the data in 15+ age 
groups, using truncated incidence rate standardized to the 
World Standard Population, so the rates are not entirely 
comparable although they are indicative of the differences 
between the studied populations. Our study showed a sig-
nificant decrease in incidence in women, while the report 
from 2017 found stagnant incidence trends between 1998 
and 2007 in the majority of countries (including Croatia, 
both men and women), apart from decreasing rates in Jap-
anese men (3). There were also countries with a significant 
increasing incidence trend in men (Thailand, Latvia, Slo-
venia, Russian Federation, Lithuania) and women (Poland, 
Latvia, Thailand, Lithuania) (3).
Our study found a slight male predominance in the in-
cidence of brain malignancies (52%). This is in line with 
the newest global incidence estimates from GLOBOCAN 
2018, which reported a higher overall incidence in men 
(55% vs 45%) (1). We also observed a significant inci-
dence trend in women. GLOBOCAN 2018 report showed 
that mortality rates in Croatian women were among the 
highest five and in men among the highest thirteen in 
the world (18). Armenia had the highest standardized 
mortality rate for women (5.0 per 100 000) and North 
Macedonia for men (9.4 per 100 000). Given these facts, 
the mortality rates in both Croatian women and men re-
main among the highest globally, and the absence of a 
decreasing mortality trend alongside the decreasing in-
cidence trend, ie, increased mortality-to-incidence ratio 
(M/I), raises the question of data validity. This finding is 
important given that the M/I ratio is sometimes used as 
a proxy of efficacy of cancer control programs (19) in the 
absence of reliable population-based survival data and 
with the good quality of incidence and mortality data. 
The increased M/I is an alarming finding and warrants re-
search into its causes and caution in interpretation of the 
results of this study.
For instance, in the absence of a confirmed histological di-
agnosis, the reliability of primary brain malignancy diagno-
sis is low, and some of these lesions might not have been 
primary brain malignancies but some other lesions. The re-
liability and different standards in collecting data on brain 
malignancies are a well-known problem in cancer regis-
tries worldwide (7).
Our data also have to be cautiously interpreted as the re-
sults of the largest study on cancer survival in the world, 
CONCORD-3, showed that 5-year net survival for patients 
diagnosed with primary brain malignancies in Croatia in 
2010-2014 period was one of the highest in Europe (42%) 
(20). Furthermore, data from the EUROCARE-5 study for 
Croatian patients diagnosed in 2000-2007 were excluded 
from the analysis (along those for Denmark, Finland, Swe-
den, Northern Ireland, Malta and some regional registries 
from Italy, Spain and Poland) due to poor data availability 
and reliability (2). Five-year survival from childhood CNS 
tumors in Croatia, analyzed separately within the EURO-
CARE-5 study, was almost 70%, with some indicators of 
overestimation (21). Very high M/I ratio and a very good 
survival are in obvious discrepancy, which is why further 
high-resolution studies are needed to elucidate these 
findings. They could be partly explained by the quality of 
mortality statistics, ie, by erroneous coding of malignan-
cies metastatic to the brain as primary brain malignancy 
(22). This is very relevant since, among European coun-
tries, Croatia has one of the highest incidences of other 
malignancies that are prone to metastasize to the brain 
(23,24). In any case, urgent efforts are needed by both 
health professionals and policy makers to improve the 
quality of care and reporting on brain malignancies, and 
to conduct further research on the strengths and caveats 
of the existing data.
The age distribution of brain malignancies and deaths is in 
accordance with the literature data (1,15). The findings of 
an age shift toward older age (85+) in incidence and mor-
tality could indicate changes in diagnostic procedures and 
treatment, but without a more specific insight into trends 
by histological subgroup this remains a speculation.
A significant decreasing incidence trend in women could 
also be interpreted as an improvement in the coding of pri-
mary cancer site in the cancer registry, however, since no 
similar changes were observed in men and the mortality 
trends did not decrease, this explanation seems less plau-
sible. A logical next step in evaluating the cancer control 
regarding brain malignancies in Croatia would be a retro-
spective study evaluating the medical histories of patients 
with brain malignancies using both hospital sources and 
cancer registry data. Also, all stakeholders should collab-
orate more closely to improve the collection of mor-
phological diagnoses for brain malignancies. This 
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could facilitate studying of brain cancer trends by histolog-
ical type, which is currently hampered by the low quality of 
data indicators in the Croatian National Cancer Registry.
The research in epidemiology of brain malignancies is rela-
tively scarce, and this is the first study to simultaneously 
quantify the incidence and mortality trends of brain malig-
nancies in Croatia. Our analysis, however, revealed signifi-
cant gaps in the quality of the existing data. To improve the 
quality of trend estimates of brain malignancies in Croatia, 
all medical professionals included in the mandatory collec-
tion of data, both for the cancer registry and official mor-
tality statistics, should deliver complete, timely, and reliable 
documents. Further research, using linkage between exist-
ing data sources, could guide future interventions with 
more precision.
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